证券代码：600211 证券简称：西藏药业 公告编号：2025-034 西藏诺迪康药业股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东大会召开的时间：2025 年 9 月 15 日 (二)股东大会召开的地点：四川省成都市锦江区三色路 427 号公司办公楼会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 700 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 62,178,322 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 30.7942 | (五)公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人；其中 3 人为公司独立董事； 2、董事会秘书出席本次会议；其他高管列席了本次会议。 二、 议案审议情况 (一)非累积投票议案 1、 议案名称：关 ...

泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会的 f 2025 年 9 月 15 日 中国•成都市天府新区隆和西巷 299 号 泰和泰中心 21—33F 21-33f, Tahota Center, No.299 Longhe West Lane, 泰和泰律师事务所 关于西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会的法律意见书 致:西藏诺迪康药业股份有限公司 散启若 泰和泰律师事务所（以下简称"泰和泰"或"本所"）作为西藏 诺迪康药业股份有限公司（以下简称"西藏药业"或"公司"）的常 年法律顾问,现接受公司的委托. 指派谭蕾、刘化勇律师出席公司 2025 年第二次临时股东大会。并依据《中华人民共和国公司法》（以下简 称"《公司法》"）《上市公司股东大会规则》（以下简称"《股东 大会规则》")《西藏诺迪康药业股份有限公司章程》（以下简称"《公 司章程》")及其他相关法律法规的规定,就公司本次股东大会的召 集、召开程序、召集人资格、出席会议人员的资格、表决程序等有关 事项出具本法律意见书。 本所律师出具法律意见,仅依据本法律意见书出具日以前发生或 者存在的事实,并基 ...

Market Overview - The biopharmaceutical sector experienced a decline of 0.7% on September 15, with Tibet Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3860.5, down 0.26%, while the Shenzhen Component Index closed at 13005.77, up 0.63% [1] Stock Performance - Notable gainers in the biopharmaceutical sector included: - Wu Fan Bio: Closed at 59.20, up 9.10% with a trading volume of 71,800 shares and a turnover of 418 million [1] - Kangchen Pharmaceutical: Closed at 57.81, up 5.24% with a trading volume of 64,400 shares and a turnover of 374 million [1] - ST Weiming: Closed at 8.39, up 5.01% with a trading volume of 77,500 shares and a turnover of 6.38 million [1] - Conversely, significant decliners included: - Tibet Pharmaceutical: Closed at 54.11, down 4.11% with a trading volume of 139,000 shares and a turnover of 773 million [2] - Junshi Biosciences: Closed at 47.43, down 2.81% with a trading volume of 176,300 shares and a turnover of 847 million [2] - Wo Wu Bio: Closed at 30.47, down 2.59% with a trading volume of 114,600 shares and a turnover of 3.55 billion [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 450 million from institutional investors, while retail investors contributed a net inflow of 190 million [2] - The capital flow for specific stocks indicated: - Changchun High-tech: Net inflow of 59.31 million from institutional investors, but a net outflow of 89.17 million from retail investors [3] - Kanghua Bio: Net inflow of 47.58 million from institutional investors, with outflows from retail investors totaling 28.74 million [3] - Kexing Pharmaceutical: Net inflow of 38.60 million from institutional investors, but a net outflow of 25.43 million from retail investors [3]

Market Overview - The biopharmaceutical sector experienced a slight increase of 0.0% on September 12, with Aopumai leading the gains [1] - The Shanghai Composite Index closed at 3883.69, up by 0.22%, while the Shenzhen Component Index closed at 12996.38, up by 0.13% [1] Top Gainers in Biopharmaceutical Sector - Aopumai (688293) closed at 54.00, with a rise of 4.73% and a trading volume of 20,300 lots, totaling a transaction value of 103 million [1] - Kexing Pharmaceutical (688136) closed at 42.28, increasing by 3.45% with a trading volume of 47,400 lots, amounting to 197 million [1] - Sanofi (688336) closed at 57.07, up by 3.39% with a trading volume of 52,600 lots, totaling 294 million [1] - Tibet Pharmaceutical (600211) closed at 56.60, rising by 3.38% with a trading volume of 93,300 lots, totaling 510 million [1] - Wenqu Pharmaceutical (688488) closed at 16.00, increasing by 2.83% with a trading volume of 86,300 lots, amounting to 134 million [1] Top Decliners in Biopharmaceutical Sector - Rongchang Biopharmaceutical (688331) closed at 107.22, down by 2.68% with a trading volume of 56,400 lots, totaling 611 million [2] - Wanze Shares (000534) closed at 16.02, decreasing by 2.61% with a trading volume of 135,500 lots, amounting to 218 million [2] - Kangtai Biopharmaceutical (300601) closed at 18.63, down by 1.48% with a trading volume of 156,700 lots, totaling 292 million [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 310 million from institutional investors, while retail investors experienced a net inflow of 132 million [2] - Notable net inflows from retail investors were observed in Kanghua Biological (300841) with 94.86 million, and Xizang Pharmaceutical (600211) with 49.76 million [3] - Conversely, significant net outflows were noted in Rongchang Biopharmaceutical (688331) with 17.13 million and Aopumai (688293) with 18.19 million from retail investors [3]

Core Viewpoint - Xizang Pharmaceutical Co., Ltd. has seen a stock price increase of 5.02%, reaching 57.50 CNY per share, with a trading volume of 633 million CNY and a turnover rate of 3.56%, resulting in a total market capitalization of 18.533 billion CNY [1] Company Overview - Xizang Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone, Tibet, and was established on July 14, 1999, with its listing date on July 21, 1999. The company primarily engages in pharmaceutical manufacturing [1] - The main revenue composition of the company is 99.80% from drug sales and 0.20% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xizang Pharmaceutical, Huaxia Fund's Huaxia Industry Prosperity Mixed Fund (003567) holds 1.9036 million shares, unchanged from the previous period, accounting for 0.59% of circulating shares. The estimated floating profit today is approximately 5.235 million CNY [2] - The Huaxia Industry Prosperity Mixed Fund was established on February 4, 2017, with a latest scale of 7.261 billion CNY. Year-to-date returns are 49.16%, ranking 881 out of 8174 in its category; the one-year return is 99.56%, ranking 463 out of 7981; and since inception, the return is 357.78% [2] Fund Management - The fund manager of Huaxia Industry Prosperity Mixed Fund is Zhong Shuai, who has been in the position for 5 years and 48 days. The total asset scale of the fund is 8.253 billion CNY, with the best fund return during his tenure being 167.61% and the worst being 8.67% [3]

Group 1 - The core viewpoint of the news is that Tibet Pharmaceutical has shown significant stock performance, with a year-to-date increase of 59.29% and a recent 10.66% rise over the last five trading days [1] - As of September 12, the stock price reached 55.86 yuan per share, with a total market capitalization of 18.005 billion yuan [1] - The company primarily engages in pharmaceutical manufacturing, with 99.80% of its revenue coming from drug sales [1] Group 2 - As of June 30, the number of shareholders decreased by 8.08% to 45,200, while the average number of circulating shares per person increased by 8.79% to 7,132 shares [2] - For the first half of 2025, Tibet Pharmaceutical reported a revenue of 1.651 billion yuan, reflecting a year-on-year growth of 2.23%, while the net profit attributable to shareholders decreased by 8.96% to 567 million yuan [2] - The company has distributed a total of 2.258 billion yuan in dividends since its A-share listing, with 1.580 billion yuan distributed over the past three years [3]

Group 1 - The company announced that it will hold the second extraordinary general meeting of shareholders on September 15, 2025 [1] - The agenda for the meeting includes the review of a proposal related to external investment involving connected transactions [1]

Core Insights - The biopharmaceutical sector experienced a 0.64% increase on September 8, with Tibet Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3826.84, up 0.38%, while the Shenzhen Component Index closed at 12666.84, up 0.61% [1] Biopharmaceutical Sector Performance - Tibet Pharmaceutical (600211) saw a closing price of 55.53, with a significant increase of 10.00% and a trading volume of 257,300 shares, amounting to a transaction value of 1.364 billion [1] - Kanghua Biological (300841) closed at 76.38, up 5.35%, with a trading volume of 63,500 shares and a transaction value of 484 million [1] - Sairun Biological (688163) closed at 25.35, up 4.71%, with a trading volume of 19,500 shares and a transaction value of 48.51 million [1] - Other notable performers include Jin Ke (688670) with a 3.35% increase, Mu Li Pharmaceutical (603087) and Wantai Biological (603392) both up 3.18% [1] Decliners in the Biopharmaceutical Sector - Sanofi Guojian (688336) experienced a decline of 6.07%, closing at 57.86, with a trading volume of 116,500 shares and a transaction value of 680 million [2] - Baiao Tai (688177) closed at 32.47, down 2.29%, with a trading volume of 37,900 shares and a transaction value of 124 million [2] - Other companies such as Yuansijinhai (836547) and Nuo Silan De (430047) also saw declines of 2.17% and 1.52% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net inflow of 76.9582 million from institutional investors, while retail investors experienced a net outflow of 56.6098 million [2][3] - Tibet Pharmaceutical had a net inflow of 246 million from institutional investors, while retail investors had a net outflow of 142 million [3] - Kanghua Biological had a net inflow of 49.0462 million from institutional investors, with retail investors experiencing a net outflow of 35.3677 million [3]

证券代码：600211 证券简称：西藏药业 公告编号：2025-033 西藏诺迪康药业股份有限公司 关于召开2025年第二次临时股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本公司于 2025 年 8 月 27 日召开第八届董事会第三次临时会议，审议通过了《关于对 外投资涉及关联交易的议案》，公司将于 2025 年 9 月 15 日召开 2025 年第二次临时股东 大会，并发布了关于召开 2025 年第二次临时股东大会的相关通知（详见公司于 2025 年 8 月 28 日发布在《中国证券报》《上海证券报》《证券时报》及上海证券交易所网站 www.sse.com.cn 的相关公告）。为确保公司股东充分了解本次股东大会的相关信息，现 将有关事项提示公告如下： 一、 召开会议的基本情况 (一)股东大会类型和届次 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的方式 (四)现场会议召开的日期、时间和地点 股东大会召开日期：2025年9月15日 本次股东大会采用的网络投票系 ...

西藏诺迪康药业股份有限公司 2025 年第二次临时股东大会文件 1 关于对外投资涉及关联交易的议案 各位股东： 企业名称：Accuredit Therapeutics Limited（成立于开曼群岛） 类型：Exempted company（豁免公司） 成立时间：2021 年 8 月 4 日 注册编号：379645 董事长：王永忠 授权资本：5 万美元 注册地：Palm Grove Unit 4, 265 Smith Road, George Town, P.O. Box 52A Edgewater Way, #1653, Grand Cayman KY1-9006, Cayman Islands 标的公司Accuredit Therapeutics Limited专注于开发基于LNP和其他非病毒载体的体内 基因编辑技术和产品，致力于为全球患者提供终生只需一次用药且具备成本优势的创新治 疗方案。该公司核心资产和主要业务集中于其在国内通过 VIE 架构控制的锐正基因（苏州） 有限公司（以下简称"锐正基因（苏州）"），从事基因编辑技术等研究。锐正基因（苏州） 目前拥有员工 46 人，王永忠担任 CEO。 为了公司 ...